Virinchi Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/08/2025 inter alia to consider and approve inter-alia to transact the following business. 1. Restructuring the SaaS business into a 100% subsidiary via slump sale to create a focused SaaS entity thus unlocking long-term shareholder value2. Divesting a portion of the SaaS business via private investment strategic partnerships or IPO and utilising proceeds to reduce debt at the consolidated level as well as invest in oncology healthcare vertical to expand the Virinchi hospital chain.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
